<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511414965</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511414965</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modelling the distribution of cortical lesions in multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sormani</surname><given-names>MariaPia</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511414965">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stromillo</surname><given-names>Maria L</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511414965">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Battaglini</surname><given-names>Marco</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511414965">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Signori</surname><given-names>Alessio</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511414965">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>De Stefano</surname><given-names>Nicola</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511414965">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511414965"><label>1</label>Biostatistics Unit, Department of Health Sciences, University of Genoa, Italy.</aff>
<aff id="aff2-1352458511414965"><label>2</label>Department of Neurological &amp; Behavioural Sciences, University of Siena, Italy.</aff>
<author-notes>
<corresp id="corresp1-1352458511414965">MariaPia Sormani, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore 1, Genoa, 16132, Italy Email: <email>mariapia.sormani@unige.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>229</fpage>
<lpage>231</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>4</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>5</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>6</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Recent studies have shown the relevance of the cerebral grey matter involvement in multiple sclerosis (MS). Cortical lesions (CLs), detected by specific MRI sequences, are likely to become a new research outcome in MS studies. The aim of this study was to infer the optimal statistical model describing the distribution of CLs in patients with relapsing–remitting (RR)MS. The negative binomial model gave the best fit to the observed distribution of CLs in a group of 44 RRMS patients with one MRI scan of the brain. This observation has important implications for the statistical analysis of CLs in MS studies.</p>
</abstract>
<kwd-group>
<kwd>cortical lesions</kwd>
<kwd>MRI</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>negative binomial distribution</kwd>
<kwd>statistical model</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511414965" sec-type="intro">
<title>Introduction</title>
<p>In patients with multiple sclerosis (MS), the number of brain demyelinating lesions as detected on MRI is considered a robust marker for assessing and monitoring disease activity. In this context, the negative binomial (NB) distribution is known as the statistical model best fitting the number of cerebral white matter (WM) lesions.<sup><xref ref-type="bibr" rid="bibr1-1352458511414965">1</xref>–<xref ref-type="bibr" rid="bibr3-1352458511414965">3</xref></sup> In particular, the NB model has been validated as the optimal distribution for modelling WM active lesions, irrespective of the disease type, effect of treatment, follow-up duration or a baseline activity selection criterion.<sup><xref ref-type="bibr" rid="bibr3-1352458511414965">3</xref></sup></p>
<p>Although MS is still classified as a disorder of the cerebral WM, recent histopathological studies<sup><xref ref-type="bibr" rid="bibr4-1352458511414965">4</xref>,<xref ref-type="bibr" rid="bibr5-1352458511414965">5</xref></sup> have shown that the involvement of the cerebral grey matter is relevant in the disease. In particular, the presence of cortical lesions (CLs) has been clearly demonstrated in these ex-vivo studies and then detected in vivo by means of specific MR sequences, providing evidence for their clinical relevance.<sup><xref ref-type="bibr" rid="bibr4-1352458511414965">4</xref>–<xref ref-type="bibr" rid="bibr8-1352458511414965">8</xref></sup> In these circumstances, it is very likely that CLs will soon become a valid outcome in MS studies, complementary to MRI WM lesions in assessing disease activity and response to therapy.<sup><xref ref-type="bibr" rid="bibr6-1352458511414965">6</xref>,<xref ref-type="bibr" rid="bibr7-1352458511414965">7</xref></sup> Thus, the objective of this study was to infer the optimal model for describing the distribution of CL counts in patients with relapsing–remitting (RR)MS. The availability of optimal statistical distribution modelling for such a new outcome measure would allow efficient design of clinical studies and the use of improved statistical analyses of group differences.</p>
</sec>
<sec id="section2-1352458511414965" sec-type="methods">
<title>Methods</title>
<sec id="section3-1352458511414965">
<title>Patients</title>
<p>We studied 44 consecutive RRMS patients, who underwent an MRI scan of the brain. The sample size was chosen to be comparable with that of a previous study assessing the same issue in white matter lesions.<sup><xref ref-type="bibr" rid="bibr1-1352458511414965">1</xref></sup> Thirty-one (78%) patients were on treatment with a disease modifying drug at the date of MRI scan. They had a mean age of 38.5 years (range 20–55), mean disease duration of 6.9 years (range 0.3–22) and median Expanded Disability Status Scale of 1.5 (range 0–5.5).</p>
</sec>
<sec id="section4-1352458511414965">
<title>MRI methods</title>
<p>As part of the conventional MRI examination, performed using a 1.5 T scanner (Achieva, Philips Medical Systems, Best, The Netherlands), all patients underwent a double inversion recovery sequence: repetition time 11.000 msec, echo time 25 msec, inversion time 3400 msec, delay 325 msec, echo train length 16.50 contiguous axial slices with a thickness of 3 mm, matrix size 256 × 256, and a field of view 250 × 250 mm. All images were assessed by consensus by two experienced observers, following the recent recommendations for CL scoring in MS patients.<sup><xref ref-type="bibr" rid="bibr8-1352458511414965">8</xref></sup></p>
</sec>
<sec id="section5-1352458511414965">
<title>Statistical analysis</title>
<p>Four models were analysed in this study: the basic Poisson and the basic NB model, the zero-inflated Poisson (ZIP) and the zero-inflated NB (ZINB). The Poisson and the NB models are well known and have been extensively described previously.<sup><xref ref-type="bibr" rid="bibr1-1352458511414965">1</xref>–<xref ref-type="bibr" rid="bibr3-1352458511414965">3</xref></sup> Zero-inflated distributions are used to model count data that have many zero counts: they are two-component mixture models combining a ‘point mass’ function at zero with a proper count distribution. Therefore zero-inflated models are based on an extra parameter representing the excess of zero counts. Testing zero-inflated models was motivated by the fact that CLs are expected to be less numerous than WM lesions, so more zeros are expected in their distribution. The Poisson model was tested because it has recently been used for the statistical analysis of CLs.<sup><xref ref-type="bibr" rid="bibr9-1352458511414965">9</xref></sup> Goodness of fit of different models was evaluated by the Bayesian Information Criterion (BIC) and the Aikaike Information Criterion (AIC) and compared by the Vuong and the likelihood ratio (LR) test. Model parameters were estimated using STATA<sup><xref ref-type="bibr" rid="bibr11-1352458511414965">11</xref></sup> routines.</p>
</sec>
</sec>
<sec id="section6-1352458511414965" sec-type="results">
<title>Results</title>
<p>A total of 73 CLs were detected in 28 out of 44 RRMS patients. Using the previously proposed scoring recommendations,<sup><xref ref-type="bibr" rid="bibr8-1352458511414965">8</xref></sup> full agreement between the two observers was reached in 66 out of 73 CLs (90%). The distribution of CL counts, reported in <xref ref-type="fig" rid="fig1-1352458511414965">Figure 1</xref> (grey bars) and in <xref ref-type="table" rid="table1-1352458511414965">Table 1</xref>, appears skewed and overdispersed. According to this, the values predicted under the assumption of a Poisson model are far from those actually observed (<xref ref-type="table" rid="table1-1352458511414965">Table 1</xref>). The best fit, according to the lowest values of both AIC and BIC criteria, was given by the NB model (<xref ref-type="table" rid="table1-1352458511414965">Table 1</xref>). In fact, even though both the NB and the ZINB models give predicted values very close to those actually observed (<xref ref-type="table" rid="table1-1352458511414965">Table 1</xref> and <xref ref-type="fig" rid="fig1-1352458511414965">Figure 1</xref>), the NB model requires the estimation of just two parameters (mean and overdispersion), while the ZINB model is based on three parameters (mean, overdispersion and extra zeros). The Vuong test indicates that the fit is not significantly improved by changing from the NB to the ZINB model (<italic>p</italic> = 0.42), suggesting that there is no extra zeros accumulation in the CLs distribution compared with what can be expected under the assumption of a NB distribution. Therefore the NB distribution is to be preferred to the ZINB model. The ZIP model performed better than the Poisson model (<italic>p</italic> = 0.065, Vuong test), the NB model performed better than the Poisson model (<italic>p</italic> &lt; 0.001, LR test) and the ZINB model was significantly better than the ZIP model (<italic>p</italic> &lt; 0.001, LR test).</p>
<fig id="fig1-1352458511414965" position="float">
<label>Figure 1.</label>
<caption>
<p>Histogram of the distribution of the number of cortical lesions and their probability distribution implied by the Poisson (red line), the zero-inflated Poisson (violet line), the Negative Binomial (green line) and the zero-inflated Negative Binomial (blue line) model. Lower BIC and the AIC criteria values indicate better fit. AIC: Aikaike Information Criterion, BIC: Bayesian Information Criterion.</p>
</caption>
<graphic xlink:href="10.1177_1352458511414965-fig1.tif"/>
</fig>
<table-wrap id="table1-1352458511414965" position="float">
<label>Table 1.</label>
<caption>
<p>Frequency of cortical lesion counts observed and predicted under the Poisson, the negative binomial, the zero-inflated Poisson and the zero-inflated negative binomial models</p>
</caption>
<graphic alternate-form-of="table1-1352458511414965" xlink:href="10.1177_1352458511414965-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Count</th>
<th align="left">Observed frequency</th>
<th align="left">Expected (Poisson)</th>
<th align="left">Expected (NB)</th>
<th align="left">Expected (ZIP)</th>
<th align="left">Expected (ZINB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.364</td>
<td>0.190</td>
<td>0.355</td>
<td>0.364</td>
<td>0.364</td>
</tr>
<tr>
<td>1</td>
<td>0.227</td>
<td>0.316</td>
<td>0.240</td>
<td>0.156</td>
<td>0.224</td>
</tr>
<tr>
<td>2</td>
<td>0.136</td>
<td>0.262</td>
<td>0.156</td>
<td>0.185</td>
<td>0.158</td>
</tr>
<tr>
<td>3</td>
<td>0.136</td>
<td>0.145</td>
<td>0.096</td>
<td>0.145</td>
<td>0.102</td>
</tr>
<tr>
<td>4</td>
<td>0.068</td>
<td>0.060</td>
<td>0.059</td>
<td>0.086</td>
<td>0.063</td>
</tr>
<tr>
<td>5</td>
<td>0.023</td>
<td>0.020</td>
<td>0.036</td>
<td>0.041</td>
<td>0.038</td>
</tr>
<tr>
<td>6</td>
<td>0.000</td>
<td>0.006</td>
<td>0.021</td>
<td>0.016</td>
<td>0.022</td>
</tr>
<tr>
<td>7</td>
<td>0.000</td>
<td>0.001</td>
<td>0.013</td>
<td>0.005</td>
<td>0.013</td>
</tr>
<tr>
<td>8</td>
<td>0.045</td>
<td>0.000</td>
<td>0.008</td>
<td>0.002</td>
<td>0.007</td>
</tr>
<tr>
<td>9</td>
<td>0.000</td>
<td>0.000</td>
<td>0.005</td>
<td>0.001</td>
<td>0.004</td>
</tr>
<tr>
<td>BIC</td>
<td/>
<td>176.750</td>
<td>162.350</td>
<td>167.370</td>
<td>165.990</td>
</tr>
<tr>
<td>AIC</td>
<td/>
<td>174.970</td>
<td>158.780</td>
<td>163.800</td>
<td>160.640</td>
</tr>
<tr>
<td>Vuong test</td>
<td align="center" colspan="5">Poisson vs. ZIP <italic>p</italic> = 0.065, NB vs. ZINB <italic>p</italic> = 0.42</td>
</tr>
<tr>
<td>LR test</td>
<td align="center" colspan="5">Poisson vs. NB <italic>p</italic> &lt; 0.001, ZIP vs. ZINB <italic>p</italic> &lt; 0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511414965">
<p>AIC: Aikaike Information Criterion, BIC: Bayesian Information Criterion, CL: cortical lesions, LR: likelihood ratio, NB: negative binomial, ZINB: zero-inflated negative binomial, ZIP: zero-inflated Poisson.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-1352458511414965" sec-type="discussion">
<title>Discussion</title>
<p>The importance of CLs in MS has recently emerged, and the statistical properties of their distribution across MS patients are not necessarily the same as for the distribution of WM lesions. In a group of RRMS patients, we tested the basic Poisson and NB models as well as zero-inflated models. As previously found in active WM lesions, the model best fitting the distribution of CLs was the NB. The use of the zero-inflated models, which should best fit distributions of counts in the presence of extra zeros, did not improve the fit. The simple Poisson model proved not to be appropriate for modelling the cross-sectional distribution of MRI CL counts, and therefore its use<sup><xref ref-type="bibr" rid="bibr9-1352458511414965">9</xref></sup> must be discouraged. This is due to the fact that the Poisson regression model increases the rate of false positive results when overdispersion is present.<sup><xref ref-type="bibr" rid="bibr10-1352458511414965">10</xref></sup></p>
<p>These results are relevant for clinical studies comparing the burden of CLs among different patient groups, evaluating its prognostic value or correlating this marker with clinical or MR variables. Further analyses are warranted to study the distribution of new CLs in longitudinal studies.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>MPS has received consulting fee or honoraria from Biogen IDEC, Merck Serono, Actelion, Synthon. MLS, MB, AS have no conflict of interests. NDS has received consulting fee or honoraria and support for travel to meetings by Merck Serono, Teva, Biogen Idec, Sanofi Aventis.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511414965">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sormani</surname><given-names>MP</given-names></name>
<name><surname>Bruzzi</surname><given-names>P</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Gasperini</surname><given-names>C</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
</person-group>. <article-title>Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials</article-title>. <source>J Neurol Sci</source> <year>1999</year>; <volume>163</volume>: <fpage>74</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511414965">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sormani</surname><given-names>MP</given-names></name>
<name><surname>Bruzzi</surname><given-names>P</given-names></name>
<name><surname>Rovaris</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Modelling new enhancing MRI lesion counts in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2001</year>; <volume>7</volume>: <fpage>298</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511414965">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van den Elskamp</surname><given-names>IJ</given-names></name>
<name><surname>Knol</surname><given-names>DL</given-names></name>
<name><surname>Uitdehaag</surname><given-names>BMJ</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
</person-group>. <article-title>The distribution of new enhancing lesion counts in multiple sclerosis: further explorations</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>42</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511414965">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
</person-group>. <article-title>Grey matter pathology in multiple sclerosis</article-title>. <source>Lancet Neurol</source> <year>2008</year>; <volume>7</volume>: <fpage>841</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511414965">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stadelmann</surname><given-names>C</given-names></name>
<name><surname>Albert</surname><given-names>M</given-names></name>
<name><surname>Wegner</surname><given-names>C</given-names></name>
<name><surname>Bruck</surname><given-names>W</given-names></name>
</person-group>. <article-title>Cortical pathology in multiple sclerosis</article-title>. <source>Curr Opin Neurol</source> <year>2008</year>; <volume>21</volume>: <fpage>229</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511414965">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>De Stefano</surname><given-names>N</given-names></name>
<name><surname>Atzori</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2007</year>; <volume>64</volume>: <fpage>1416</fpage>–<lpage>1422</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511414965">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
<name><surname>Gallo</surname><given-names>P</given-names></name>
</person-group>. <article-title>Cortical lesions in multiple sclerosis</article-title>. <source>Nat Rev Neurol</source> <year>2010</year>; <volume>6</volume>: <fpage>438</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511414965">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Roosendaal</surname><given-names>SD</given-names></name>
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>418</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511414965">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Absinta</surname><given-names>M</given-names></name>
<name><surname>Rocca</surname><given-names>MA</given-names></name>
<name><surname>Moiola</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Cortical lesions in children with multiple sclerosis</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>910</fpage>–<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511414965">
<label>10.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Cook</surname><given-names>R</given-names></name>
<name><surname>Lawless</surname><given-names>J</given-names></name>
</person-group>. <source>The statistical analysis of recurrent events</source>. <publisher-name>Springer-Verlag, New York Inc.</publisher-name>, <year>2007</year>.</citation>
</ref>
<ref id="bibr11-1352458511414965">
<label>11.</label>
<citation citation-type="book">
<collab>StataCorp</collab>. <year>2009</year>. <article-title>Stata Statistical Software: Release 11</article-title>. <publisher-loc>College Station, TX</publisher-loc>: <publisher-name>StataCorp LP</publisher-name>.</citation>
</ref>
</ref-list>
</back>
</article>